A.P.L.
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
A.P.L. is a biologic injectable approved in 1974 by Ferring Pharmaceuticals with an unknown mechanism of action and indication profile. Specific therapeutic uses and patient populations cannot be determined from available data.
LOE Approaching
This is a legacy biologic entering loss-of-exclusivity; expect defensive positioning and smaller commercial team focused on market share retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
A.P.L. has zero linked job openings, reflecting its mature LOE-approaching status. Career opportunities focus on defensive commercialization, payer negotiations, and lifecycle management rather than growth or innovation roles.
Brand ManagerField Sales Representative
Worked on A.P.L. at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.